Here we report new papers citing DRAQ7™ in cancer research showing its spectrum of performance.
DRAQ7 is demonstrated in a T-cell cytotoxicity assay, monitoring target cell death in real-time. DRAQ7 doesn't exhibit any bystander toxicity, yet efficiently enters permeabilised cells.
DRAQ7 was employed to monitor cell killing of viral tumour hepatoma targets with and without knockdown of PD-1 on antigen-specific T cells prior to and 24h after the addition of the T cells.
Otano, Itziar, et al. "Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver." Molecular Therapy (2018).
DRAQ7 acts as a classical viability dye in flow cytometric apoptosis assays. It readily replaces PI, 7-AAD or DAPI and has been shown to have improved s:n (Beckman Coulter application note) and frees up valuable space for common visible-range chromophores.
DRAQ7 was combined with Annexin V (FITC) to calculate apoptosis following treatment with different ITK inhibitors analysed on the BD Biosciences FACSCanto II. Mamand, Sami, et al. "Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma." Scientific reports 8.1 (2018): 14216.
Two papers further demonstrate DRAQ7 with the Sartorius Incucyte ZOOM. It allows Monitoring cell health (or death) in real-time/time-lapse over several days. Chemical stability, buffer compatibility and red excitation are all valuable features in this application area.
DRAQ7 was combined with Annexin V (FITC) to calculate apoptosis following treatment with different ITK inhibitors analysed on the BD Biosciences FACSCanto II. Mamand, Sami, et al. "Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma." Scientific reports 8.1 (2018): 14216.
Two papers further demonstrate DRAQ7 with the Sartorius Incucyte ZOOM. It allows Monitoring cell health (or death) in real-time/time-lapse over several days. Chemical stability, buffer compatibility and red excitation are all valuable features in this application area.
DRAQ7 was used to monitor cell death over a 48 h time course in ER+ breast cancer cell lines (fulvestrant sensitive and resistant) treated with a PI3Kα inhibitor.
Stratikopoulos, Elias E., et al. "Mouse ER+/PIK3CA H1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents." Oncogene (2018): 1.
DRAQ7 was used to score the response of knockdown and expression variants of A375 cells to nitrofuran NFN1 +/- ALDH-inhibitor DEAB, over 72 hours exposure, read at 3-hourly intervals.
Sarvi, Sana, et al. "ALDH1 Bio-activates Nifuroxazide to Eradicate ALDH-high Melanoma-Initiating Cells." Cell chemical biology (2018).
DRAQ7 works in multi-parameter cell death modality analysis by Imagestream. Spectral separation and clean segmentation of dsDNA are key factors in its choice for the Imagestream.
Cell membrane permeabilization (DRAQ7-positivity and associated nuclear morphology) was monitored as part of a multi-parametric analysis of cell death modalities using imaging flow cytometry (Merck Imagestream), and in the context of different anti-cancer therapies.
Martins, Isabelle, et al. "Anticancer chemotherapy and radiotherapy trigger both non-cell-autonomous and cell-autonomous death." Cell death & disease 9.7 (2018): 716.
In addition, DRAQ7 has been proven in complex flow cytometry panels for dead cell exclusion (post hoc, if necessary!) and to ensure delivery of intact cells in sorting for downstream RNA-seq and GWAS; see the white paper and related blog article.
No comments :
Post a Comment